PTHL: Pheton Holdings Company Value to Net Income

Corporate emblem and logo of Pheton Holdings (PTHL)

Pheton Holdings Ltd (PTHL) is establishing a prestigious image within the Chinese biotech sector, sparking significant interest from medical circles in its research. The company supplies specialized software and materials for brachytherapy, generating profit from needle sales and the lock-in of clinics to its planning systems. This chart featuring the -3.60 metric confirms its market positions. High barriers to entry are created by algorithmic patents and stringent safety standards in nuclear medicine.

PTHL Pheton Holdings Limited: Price to Earnings Ratio in the range 09/06/2024 - 01/16/2026

Comprehensive metric breakdowns and analytics for Pheton Holdings Limited (PTHL)

- price and consensus price forecast:
- market capitalization information:
Comprehensive company analysis:Pheton Holdings Limited - PTHL
Flagship merchandise of Pheton Holdings

The assessment of investment reliability for equity assets is based on an analysis of market value relative to net income, which determines the extent of the premium paid for future growth. This ratio measures the efficiency of earnings capitalization, and in the context of optimizing Asian supplies, the monthly P/E dynamics of Pheton Holdings Ltd (PTHL) reflect market expectations regarding reduced cost of sales and improved business margins.

Analysis of competing companies

HLN: Company Value to Net Income|Price to Earnings Ratio KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Limited MENS|Ligand (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|Perrigo - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Technologies - Company Value to Net Income|GLPG (Galapagos N.V.) - P/E Multiple|Market Cap to Earnings anipharmaceuticals.com ANIP|Price to Earnings Ratio MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Company Value to Net Income|Price to Earnings Ratio Pacira BioSciences, Inc. PCRX|P/E Multiple ARS Corp SPRY|Theravance Biopharma - P/E Multiple|Market Cap to Net Income Ratio Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Price to Earnings Ratio|Price to Earnings Ratio Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals Holding) - P/E Multiple|Price to Earnings Multiple SXTC (China SXT Pharmaceuticals)|P/E Multiple EPRX|P/E Multiple bioharvest.com (BHST)|Price to Earnings Ratio Invizyne Technologies EXOZ|ORMP: Price to Earnings Multiple|ENTX: Price to Earnings Ratio|HYFT: Price to Earnings Ratio|ABVC BioPharma Inc. (ABVC) - Price to Earnings Ratio|cumberlandpharma.com (CPIX) - P/E Multiple|QNTM (Quantum BioPharma) - P/E Multiple|FGEN: Company Value to Net Income|P/E Multiple TELO|P/E Multiple Rani Therapeutics Holdings (RANI)|P/E Multiple SNYR (Synergy CHC Corp)|Rallybio Corporation (RLYB) - Market Cap to Earnings|LEXX - Price to Earnings Ratio|PULM (Pulmatrix) - Price to Earnings Multiple|APM (Aptorum) - Price to Earnings Ratio|Lyra Therapeutics, Inc. (LYRA) - P/E Multiple|IBO (impactbiomedinc.com) - P/E Multiple|TNFA (TNF Pharmaceuticals) - Market Price to Net Income Ratio|Price to Earnings Ratio cbdmd.com (YCBD)|Business Payback Period PainReform Ltd|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Market Cap to Earnings|OPTN - Price to Earnings Ratio|Pieris Pharmaceuticals - Market Price to Net Income Ratio|PROC (Procaps Group) - Price to Earnings Ratio|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding Group Limited|SLRN: Company Value to Net Income|Price to Earnings Ratio TFFP (TFF Pharma)